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Introduction
Equine infectious anemia virus (EIAV) possesses com-
mon features of the Lentiviridae subfamily of retroviruses, 
including a complex genome organization, tropism for cells 
of the monocyte/macrophage lineage, and establishment of 
a persistent, life-long infection. Many lentivirus infections 
are characterized by a slow, chronic disease, but infection 
of horses with EIAV can result in an acute, dynamic disease 
course characterized by recurring cycles of viremia, fever, 
and thrombocytopenia, with a possible development of 
anemia (reviewed in Issel and Coggins, 1979). Fever cycles 
are typically irregular and may recur for up to 1 year, de-
spite the onset of a neutralizing- antibody response. Horses 
which survive these initial clinical episodes become life-
long, inapparent carriers of the virus. The variable nature 
of clinical disease and the fact that most infected horses are 
able to control virus replication and remain life-long inap-
parent carriers make EIAV infection an excellent model for 
studies of virus and host factors which contribute to lentivi-
rus persistence and pathogenesis.
Virus persistence over a life-long infection is dependent 
on both host and viral factors. Genetic variation, the result 
of errors produced by reverse transcriptase, is a well-stud-
ied mechanism of lentivirus persistence (Hubner et al., 
1992; Ji and Loeb, 1994; Nowak, 1990; Patel and Pres-
ton, 1994). The result of the genetic variation is the accu-
mulation of nonidentical, yet related, variants commonly 
referred to as a quasispecies (Domingo et al., 1996; Eigen, 
1993; Holland et al., 1992). Selection acts on the quasi-
species population, and the diversity within the popula-
tion allows the virus to adapt to changes in selective pres-
sures. The quasispecies nature of EIAV is largely the result 
of three regions of hypervariability: the viral long termi-
nal repeat (LTR), the surface envelope (SU), and a region 
where the major exon of Rev is completely overlapped 
by the transmembrane protein (TM). Variation in SU, re-
sulting from mutations, insertions, or duplications within 
the principal neutralization domain or hypervariable re-
gion, can alter antigenicity and facilitate evasion of host 
immune surveillance (Payne et al., 1984, 1987, 1989; 
Kono, 1969, 1972; Salinovich et al., 1986; Perryman et 
al., 1988; Montelaro et al., 1990; Issel et al., 1990; Kono 
et al., 1973; Zheng et al., 1997). Studies examining the 
immune response of EIAV-infected horses indicate that 
both cellular and humoral immune responses contrib-
Published in Virology 279:1 (January 5, 2001), pp. 185–200; doi 10.1006/viro.2000.0696   
Copyright © 2001 Academic Press/Elsevier. Used by permission. http://www.sciencedirect.com/science/journal/00426822
Submitted July 10, 2000; revised September 8, 2000; accepted October 3, 2000; published online March 12, 2002.
Genetic and Biological Variation in Equine Infectious Anemia  
Virus Rev Correlates with Variable Stages of Clinical Disease  
in an Experimentally Infected Pony
Michael Belshan,1 Prasith Baccam,1,2 J. Lindsay Oaks,3 Brett A. Sponseller,1  
Sean C. Murphy,1 James Cornette,2 and Susan Carpenter 2
1 Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, Iowa, 50011
2 Department of Mathematics, Iowa State University, Ames, Iowa, 50011
3 Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington, 99164
Corresponding author — S. Carpenter, Department of VMPM, Iowa State University, Room 1136 Vet Med,  
South 16th Street, Ames, IA 50011. Fax (515) 294-8500; Email scarp@iastate.edu
Abstract
Genetic and biological variation in the regulatory protein Rev of equine infectious anemia virus (EIAV) were examined throughout a 
clinically dynamic disease course of an experimentally infected pony. Following infection with the virulent EIAVWyo, the pony under-
went a variable disease course, including an acute fever episode at 12 days postinfection (DPI), multiple recurrent fever episodes until 
135 DPI, a prolonged subclinical period, and two late fever episodes. Viral RNA was isolated from the inoculum and sequential sera 
samples, and the rev exon 2/gp45 overlapping ORFs were amplified, cloned, and sequenced. Novel variants were found throughout 
infection, and genetic analyses indicated that both the Rev and gp45 ORFs were under selective pressure. The Rev variant predom-
inant in the inoculum, R1, remained predominant during the early periods following infection (until 35 DPI); however, R1 was re-
placed by new predominant variants during the recurrent fever period (67–135 DPI). R1 reemerged as the predominant variant during 
the afebrile period, but a new predominant variant, R93, was associated with the late fever episodes. Rev variants predominant during 
recurrent febrile and late-febrile periods had significantly higher Rev-mediated nuclear export activity than the variants predominant 
during the acute and afebrile periods. Statistical correlation was found between Rev activity and different stages of clinical disease. 
Together, these results suggest that genetic and biological variation in rev may be a contributing factor in EIAV disease progression. 
Keywords: EIAV, Rev, persistence, quasispecies, variation, evolution
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ute to suppression of virus replication during inapparent 
stages of infection (Salinovich et al., 1986; Hammond et 
al., 1997). No subset of the immune response, however, 
was ever previously shown to specifically correlate with 
control of virus replication during long-term persistence 
(Hammond et al., 1997).
Lentiviruses have evolved complex mechanisms to reg-
ulate viral gene expression at the transcriptional and post-
transcriptional levels. Variation in regulatory elements 
such as the LTR and Rev may alter the level of virus gene 
expression and, subsequently, viral replication (Carpenter 
et al., 1991; Alexandersen and Carpenter, 1991; Maury et 
al., 1997). We and others described genetic variation in 
the second exon of the EIAV regulatory protein Rev (Alex-
andersen and Carpenter, 1991; Belshan et al., 1998; Le-
roux et al., 1997), but the biological significance of Rev 
variation in vivo has not yet been explored. Rev functions 
to facilitate the nuclear export of the incompletely spliced 
viral RNAs during the late phase of virus replication. 
These viral RNAs encode the structural proteins and serve 
as progeny RNA molecules. Rev-dependent RNA export 
pathways have been described for numerous lentiviruses 
(reviewed in Cullen, 1992; Hope, 1997), and the human 
immunodeficiency virus type 1 (HIV-1) Rev-mediated ex-
port pathway is the best characterized. HIV-1 Rev binds a 
structure in the viral pre-mRNA, called the Rev-responsive 
element (RRE) (Zapp and Green, 1989), multimerizes (Ol-
sen et al., 1990), then utilizes the CRM1 nuclear export 
pathway to redirect movement of incompletely spliced vi-
ral RNA from the nucleus (Fornerod et al., 1997; Stade et 
al., 1997; Bogerd et al., 1995; Stutz et al., 1995). Discrete 
functional domains within Rev that mediate its interaction 
with cellular proteins and viral RNA are required for nu-
clear localization, RNA binding, multimerization, and nu-
clear export. EIAV Rev is a 165 amino acid protein func-
tionally homologous to HIV-1 Rev (Fridell et al., 1993). 
The major exon encodes for the nuclear export signal of 
EIAV Rev, amino acids 2–25 (Fridell et al., 1993) and was 
previously shown to be able to substitute for the HIV-1 
or visna virus effector domains (Fridell et al., 1993; Man-
cuso et al., 1994). A putative nuclear localization signal 
was previously mapped to the arginine-rich C-terminus of 
EIAV Rev (Harris et al., 1998).
Rev is absolutely required for expression of viral struc-
tural genes and production of new virus. Therefore, fac-
tors which modulate Rev activity and, consequently, alter 
levels of viral gene expression may be important in regu-
lating virus replication in vivo. Rev-attenuated phenotypes 
were previously identified during asymptomatic stages of 
HIV-1 infection, suggesting that variation in Rev could al-
ter virus replication levels in vivo and contribute to the 
clinical outcome of infection (Iversen et al., 1995; Hua 
et al., 1996). We previously identified extensive nucleo-
tide substitutions in the second exon of EIAV rev in virus 
obtained from an experimentally infected horse (Alexan-
dersen and Carpenter, 1991). The coexistence of putative 
Rev-competent and Rev-deficient phenotypes suggested 
that variation in Rev may contribute to virus persistence 
through regulation of virus replication. Subsequent in vi-
tro analysis indicated that limited amino acid variation 
in Rev could alter Rev-mediated nuclear export activity 
(Belshan et al., 1998), further suggesting that variation in 
Rev may modulate virus replication during disease.
In the present study, we undertook extensive genetic 
and biological analyses of Rev quasispecies during long-
term persistence in a single experimentally infected pony. 
Consistent with previous studies (Leroux et al., 1997), 
novel rev variants were detected throughout infection. Sig-
nificantly, changes in the genotype and phenotype of Rev 
quasispecies correlated with changes in clinical stages of 
EIAV infection. These findings indicate that genetic and 
biological changes in Rev contributed to the selection of 
EIAV variants in vivo, and may be important factors in len-
tivirus persistence and pathogenesis.
Results
Clinical profile of EIAVWyo-infected pony 524
To accurately reflect the genetic diversity of an in vivo 
infection, pony 524 was inoculated with the highly viru-
lent Wyoming strain of EIAV (EIAVWyo), which has been 
maintained by serial in vivo passage (Oaks et al., 1998). 
This inoculum represents a heterogeneous population 
of virus, similar to a natural infection. After inoculation, 
pony 524 experienced a clinical disease course charac-
terized by recurring fever cycles interspersed with afebrile 
periods ranging from days to months (Figure 1A). The ini-
tial acute episode included a biphasic febrile response 
and thrombocytopenia from 10 to 22 days postinfection 
(DPI). The pony was then afebrile until 39 DPI. Thereaf-
ter, pony 524 underwent a period of seven recurrent fever 
episodes, which ranged from 2 to 6 days in length. The 
last fever episode ended after Day 135, and pony 524 re-
mained afebrile except for two late fever episodes at Days 
565 and 799. Febrile episodes were defined as rectal tem-
perature greater than or equal to 101°F. Thrombocytope-
nia (platelet count less than 105 platelets/ml) was also ob-
served concurrent with the initial fever cycles. After the 
initial fever cycles subsided, pony 524 remained persis-
tently thrombocytopenic throughout the experiment. Ex-
cept for the fever and thrombocytopenia, no other clinical 
signs were observed.
Semiquantitative RT-PCR was used to monitor virus 
levels at various DPI (Figure 1B). Consistent with previ-
ous reports, high virus loads were found in the initial fe-
ver period at 12 DPI but fell to a nearly undetectable level 
during the afebrile interval at 35 DPI. The highest virus 
load, 9.08 × 107 copies RNA/ml, was detected during the 
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recurrent febrile period at 67 DPI. Levels of plasma viral 
RNA decreased somewhat in the subclinical period and 
were barely detectable at 754 DPI. However, virus re-
bounded to 1.38 × 105 copies/ml at 800 DPI. Virus neu-
tralization assays to EIAVWSU-5, a cell-culture-derived 
strain of EIAVWyo (O’Rourke et al., 1988), indicated that 
broadly reacting neutralizing antibodies appeared after 
the chronic fever cycles subsided (201 DPI) (Figure 1C). 
Pony 524 maintained elevated neutralizing antibody to 
EIAVWSU-5 throughout the remainder of the experiment.
Quasispecies distribution of the inoculum and statistical 
analysis of sampling procedure
A potential problem with current methods used to 
characterize viral variants is the possible selection of a 
subpopulation of variants that may not be reflective of the 
population present in vivo. To confirm that the selected 
primer pairs did not bias the distribution of observed vari-
ants, statistical analyses were performed on the distribu-
tion of variants obtained by RT-PCR amplification of the 
inoculum. Sequences were amplified using four different 
sets of primer pairs (Table 1), designed from conserved 
regions flanking exon 2 of rev. Chi-square analyses indi-
cated that the frequency of observed variants in the in-
oculum was not systematically biased during PCR am-
plification (not shown). Thus, the observed quasispecies 
population is likely to be reflective of variant frequencies 
in vivo.
A total of 61 individual clones, at least 10 from each 
primer pair, were sequenced from the EIAVWyo inocu-
lum. At the nucleotide level, 39 different genotypes were 
detected and translated into both the Rev and the gp45 
ORFs. A total of 25 different Rev amino acid variants, des-
ignated R1 through R25, were observed in the Rev ORF 
(Figure 2). Five genotypes were observed at a frequency 
greater than 1, and two clones, R1 and R2, accounted 
for 30 and 25% of the sample population, respectively. 
Translation in the gp45 ORF identified 30 different vari-
ants, designated E1–E30 (Figure 2). The increased number 
of variants in gp45 as compared to Rev was primarily the 
result of an R to Q change at position 129 of gp45, which 
Figure 1. Clinical and serological profile of pony 524. (A) Clinical profile 
of EIAVWyo-infected pony 524, including platelet counts (gray line, pri-
mary y-axis) and fever episodes (columns, secondary y-axis). Fever was 
defined as rectal temperature greater than or equal to 101°F. (B) Virus 
load, as measured by copies of RNA/ml serum, was determined by semi-
quantitative RT-PCR for the days indicated by open circles. (C) Virus neu-
tralizing (VN) antibody titer of pony 524 to EIAVWSU-5. VN titers were de-
termined as described under Materials and Methods from serum samples 
obtained at 0, 11, 35, 67, 89, 118, 201, 289, 498, 754, and 800 DPI. 
TABLE 1. Primer Pairs Used for Amplification of EIAV Rev 
Sequences
Primer        Primer
pair            namea                   Primer sequence (5′–3′)
1  EM 7066  CAATTTGGCACAATCCATGA
 EM 7674C  GCGAGAGTTCCTTCTTGGGC
2  EM 7066  CAATTTGGCACAATCCATGA
 EM 7680CRI  GGAATTCCGAGAGTTCCTTCTTGG
3  EM 7160  GGATTGGGAGCTTCCATTAT
 EM 7674C  GCGAGAGTTCCTTCTTGGGC
4  EM 7160  GGATTGGGAGCTTCCATTAT
 EM 7680CR1  GGAATTCCGAGAGTTCCTTCTTGG
a C indicates the primer is on the complementary (antisense) strand, and 
R1 indicates the presence of an EcoRI restriction site (underlined) at the 
3′ end. 
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was a silent change in the Rev ORF. Eight gp45 genotypes 
were observed more than once, and the predominant vari-
ant, E1, accounted for 16% (10/ 61) of the population.
Genetic changes in rev/gp45
To analyze variation throughout infection, RNA was iso-
lated from the inoculum and from sera samples collected 
at various stages of clinical disease, including: acute fe-
brile (12 DPI), first afebrile interval (35 DPI), recurrent fe-
brile (67, 89, and 118 DPI), afebrile (201, 289, 385, and 
437 DPI), and late febrile (754 and 800 DPI) periods. The 
rev exon 2/gp45 overlapping region of EIAV was ampli-
fied using primer pairs 2 and (Table 1), and 22 to 26 in-
dividual clones were sequenced at each time point. Se-
quences from each time point represent data from two 
independent RT-PCR reactions. Novel variants were de-
tected at each time point, and the greatest number of new 
variants was observed at 67, 89, 118, and 201 DPI, corre-
sponding to the recurrent fever period and the first sample 
of the afebrile period (Table 2).
The amplified region contains overlapping reading 
frames for two viral proteins, and we used a variety of ge-
netic analyses to evaluate the potential significance of 
genetic changes in each reading frame. Consistent with 
observations of other retroviruses (Kim et al., 1996), we 
observed a high ratio of transition (Ts) to transversion (Tv) 
at each time point. There was also a high ratio of nonsyn-
Figure 2. Frequency and distribution of Rev and gp45 sequences in EIAVWyo inoculum. rev/gp45 was amplified from the inoculum and 61 clones were 
sequenced and translated into the Rev and gp45 open reading frames. The variant identity (V) and the number of clones of each variant (N) are given 
for each reading frame. The sequence of the dominant variant (R1 or EI) is given, and the changes in amino acid sequence in all other variants are 
shown. ( · ) Indicates an identical aa to R1 or EI at that position and ( – ) indicates a –1 frameshift mutation. 
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onymous (N) to synonymous (S) mutations in both ORFs 
of the overlapping region (Table 2). At most time points, 
the N/S ratio was similar for both reading frames, although 
disproportionate values were sometimes observed. At Day 
437, for example, there were 15 nt changes in all the se-
quences: in the Rev ORF, there was one change in the first 
codon position, seven in the second codon position, and 
seven in the third codon position. One of the changes in 
the third codon occurred concurrent with a second co-
don change, resulting in six synonymous changes in Rev 
and nine nonsynonymous changes, or an N/S of 1.5. In 
the gp45 reading frame, the codon positions change with 
respect to Rev, resulting in seven changes in the first co-
don position, seven in the second codon position, and 
one in the third codon position, resulting in an N/S ratio 
of 14/1 for Env. The overall N/S ratio was greater than 1 
for both Rev (1.54) and gp45 (2.15), suggesting that vari-
ation in this region was the result of selective pressure. 
Application of the Tajima test (Tajima, 1989), which is a 
widely used procedure to determine whether nucleotide 
variation within a region was the result of either selective 
pressure or neutral mutations, confirmed that this region 
was indeed under selective pressure. Together, the results 
of the genetic analyses indicated a continuing evolution 
in Rev and gp45 throughout infection, with changes re-
sulting from selective pressure in both reading frames.
Rev variation throughout clinical disease
The genetic analyses suggested that variation in Rev 
was the result of selection rather than neutral mutations. 
We previously showed that genetic variation could alter 
Rev activity, and we focused our subsequent analyses on 
variation in the Rev ORF. Rev amino acid sequences were 
examined from the inoculum (Figure 2) and from each of 
the 11 time points following infection (Figure 3). As de-
scribed above, the inoculum was predominated by two 
Rev amino acid variants, R1 and R2, which accounted for 
30 and 25% of the sample population, respectively. The 
consensus sequence for the inoculum was identical to 
the sequence of R1. The genetic variation observed was 
not distributed uniformly across Rev, and there were two 
main regions of variability. Few changes were observed 
in the nuclear export sequence, which was previously 
mapped to aa 2–25 (Fridell et al., 1993; Mancuso et al., 
1994). However, amino acid position 25, located at the 
C-terminus of the nuclear export signal, was highly vari-
able, with either a consensus serine or a leucine mutation 
at that position (S25L). At positions 104–108, there was 
a GDYQQ consensus sequence, with DGYQR appearing 
in a small number of variants. The C-terminal region of 
EIAV rev is highly basic, and a putative nuclear localiza-
tion signal was previously mapped to this region (Harris et 
al., 1998). There were only two changes in the C-terminal 
region, and both changes retained or increased the basic 
character of this region. Changes in the Rev quasispecies 
were examined at varying stages of clinical EIAV. 
Acute stage. The consensus sequence of R1 was used 
as the standard by which the subsequent sera samples 
were compared. During the early period after infection, 
there were no changes in the consensus sequence (Figures 
3 and 4). The Rev quasispecies found in the initial febrile 
episode at 12 DPI was genetically very homogeneous. The 
variant R1 remained the predominant variant, accounting 
Table 2. Genetic Analysis of Variation in rev and gp45 ORFs
                                                      Days postinoculation (DPI)
  Inoc.  12  35  67  89  118  201  289  385  437  754  800 Total 
 Total clonesa  61  24  23  23  24  24  25  22  26  23  24  23  322
NTb  Variantsc  39  13  12  14  20  15  20  9  15  12  11  13
 New variantsd  39  10  7  9  17  12  15  4  10  6  7  9  145
Revb  Variantsc  25  7  11  13  18  11  16  8  12  6  7  8
 New variantsd  25  6  7  9  14  8  12  3  7  1  5  4  101
 N/Se  1.0  0.9  7  2.2  2.6  1.9  2.4  1.8  2.1  1.5  2.0  1.2
gp45b  Variantsc  30  7  10  14  16  11  15  8  10  12  8  11
 New variantsd  30  5  4  11  12  7  10  2  4  6  5  9  105
 N/Se  2.3  1.2  2.2  4.0  1.8  1.9  4.2  3.2  2.1  14  3.4  7.7
a Number of clones sequenced at each time point.
b Analysis of variation in nucleotide sequence (NT) or amino acid sequence in the Rev or gp45 open reading frame.
c Number of distinct genotypes present at each time point.
d Number of new genotypes not previously observed.
e Ratio of nonsynonymous to synonymous mutations in that ORF.
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Figure 3. Alignment of Rev aa sequences obtained from sera of pony 524 at 12, 35, 67, 89, 118, 201, 289, 385, 437, 754, and 800 DPI. The vari-
ant identity (V) and number of clones of each variant (N) are given for each time point, as well as the total number of clones sequenced (below the N 
column). Dominant variants are highlighted in bold. Sequences are compared to R1, which is listed at the top of each time point. For individual se-
quences, ( · ) indicates an identical aa to R1 at that position, (*) indicates a premature stop codon in the Rev ORF, and (+) indicates a +1 frameshift.
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Figure 3, continued. 
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for 75% of the sample population. The remaining six vari-
ants had not been observed in the inoculum, and each 
differed from R1 by a single amino acid. None of the vari-
ants contained changes at aa 25 or in the GDYQQ region 
at 104–108. In the intervening afebrile period at 35 DPI, 
the quasispecies resembled the inoculum. Both R1 and 
R2 variants were detected, and the former was again the 
predominant variant. Also, we observed two minor vari-
ants which had been present in inoculum (R14, R17), and 
genetic variability was detected at position 25 (S or L) and 
in the DGYQR motif at aa 104–108.
Recurrent febrile stage. The Rev quasispecies observed 
in the recurrent febrile period (67, 89, and 118 DPI) dif-
fered markedly from the previous populations, as re-
flected in the appearance of a new consensus sequence 
at each time point sampled (Figure 4). Notably, the vari-
ant R1, which predominated both the inoculum and the 
samples from 12 and 35 DPI, was not detected in any of 
the three samples taken during the recurrent febrile stage. 
Variants and/or amino acid changes present as minor 
populations in earlier time points grew in frequency to 
predominate during the recurrent febrile period. For ex-
ample, variant R32 was only a minor variant at 35 DPI 
but represented 43% of the population at 67 DPI. The 
consensus sequence at 67 DPI was identical to that of 
R32 and had an alanine at aa 82 as well as the DGYQR 
motif in region 104–108. At 89 DPI, R32 had decreased 
to 14% of the population, and no variant accounted for 
more than 20% of the population at this time point. The 
consensus sequence at 89 DPI contained a GGYQR mo-
tif and was represented by the variant R12, a minor vari-
ant which was also present in the inoculum and 67 DPI. 
R53 was present as a minor variant at 89 DPI and grew 
to predominate the quasispecies population at 118 DPI. 
R53 shared the consensus sequence at 118 DPI, which 
contained an R97K substitution and a GGYQR motif in 
region 104–108. Throughout the recurrent febrile period, 
minor variants were observed which contained amino 
acid substitutions in the NES, although none contained 
the R2-like S25L. In summary, the recurrent febrile period 
was characterized by continual changes in the consensus 
sequence, with minor variants growing to predominate at 
subsequent time points.
Afebrile stage. The first serum sample analyzed after 
the recurrent febrile episodes subsided was obtained at 
201 DPI, and no variant accounted for more than 20% 
of the population at this time point. Surprisingly, after go-
ing undetected throughout the recurrent febrile period, 
R1 was observed as a minor variant. Although R2, R17, 
and R32 were also present as minor variants, the consen-
sus sequence at 201 DPI was unlike those previously ob-
served. The sequence of R78 was identical to the consen-
sus sequence at 201 DPI and consisted of G80D, R97K, 
and Q108R. Position 25 was highly variable, with several 
variants containing a proline at that residue. At aa 104–
108, both the GDYQQ and the DGYQR motifs were de-
tected in addition to the consensus sequence containing 
GDYQR. After 201 DPI, the frequency of R1 grew to pre-
dominate each time point analyzed during the remainder 
of the afebrile period (289, 385, and 437 DPI), and the 
consensus sequence was identical to that of R1 at each of 
these time points. Overall, the identity of the minor vari-
ants was not highly variable during the afebrile stage, with 
R17, R32, and R33 observed in most of the samples. In 
contrast to the continual appearance and growth of minor 
variants in the recurrent febrile stage, the afebrile stage 
was relatively stable genetically and predominated by R1.
Late febrile stage. Two late fever episodes occurred at 
565 and 799 DPI. Analysis of rev variation included sam-
ples collected at 754 and 800 DPI. R1 was observed as 
a minor variant at 754 DPI but was not detected at 800 
DPI. A new variant, R93, arose as the predominant vari-
ant and the consensus sequence at 754 and 800 DPI and 
differed from R1 by seven amino acids. Changes not ob-
served in previous consensus sequences included L25P, 
V75A, and R112H. Other changes from R1 found in the 
consensus sequence for 754 and 800 DPI were G80D, 
R97K, D105G, and Q108R, which had been part of ear-
lier consensus sequences.
In summary, the dynamics of the Rev quasispecies evo-
lution were reflected by the changes in the consensus se-
quences during the course of disease (Figure 4). These 
changes were exemplified by the disappearance and re-
appearance of R1, which was identical to the consensus 
sequence in the acute fever episode, the first afebrile in-
terval, and most of the afebrile period. The replacement 
Figure 4. Consensus Rev aa sequences at each time point (DPI). The variant identity (V) and sequence, relative to R1, are given for each time point. At 
two time points, 89 and 201 DPI, no variant was predominant and the consensus sequence was represented by a minor variant, indicated by (*). 
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of R1 by novel variants during both the recurrent and late 
febrile periods is reflected in changes in the consensus se-
quence during those clinical stages of EIAV infection. The 
finding that changes in rev consensus sequences coin-
cided with changes in the clinical disease suggested dif-
ferences in selective pressures at sequential stages of dis-
ease. Surprisingly, these results suggested that the host 
environment in the acute and afebrile stages selected for 
similar Rev variants. 
Biological activity of Rev quasispecies 
Genetic analysis of rev variation suggested differences 
in selective pressure at different stages of clinical disease. 
Therefore, it was important to determine the biological 
activity of Rev variants observed in this study. Because it 
was not practical to biologically test each clone, Rev vari-
ants which were predominant or representative of con-
sensus sequences at any time point were cloned into a 
eukaryotic expression vector containing rev exon 1. The 
Rev-mediated nuclear export activity was determined 
in transient transfection assays as previously described 
(Belshan et al., 1998) and results were normalized to R1 
(Figure 5A). R2, which contained the single S25L change 
from R1, exhibited a level of activity similar to that of R1. 
The variant R26 (R52G), which was detected at 12, 118, 
and 754 DPI, was the only variant tested that had signifi-
cantly lower Rev activity (63%) than did R1. Interestingly, 
all other variants assayed showed levels of nuclear ex-
port activity that were significantly higher than that of R1 
(P < 0.05). These included variants that were identical to 
the consensus sequences during the recurrent febrile and 
late febrile stages of disease (67, 89, 118, 754, and 800 
DPI). The consensus sequences represented by the vari-
ants R12, R32, R53, and R93 all exhibited approximately 
165% activity relative to that of R1. Other variants tested 
from the recurrent febrile stage, R42, R45, and R51, also 
had Rev activity approximately 175%. Thus, the recurrent 
and late febrile periods were predominated by Rev vari-
ants that had significantly higher nuclear export activity 
than that of R1, which predominated the acute and afe-
brile periods. Interestingly, 201 DPI was characterized 
by the coexistence of Rev variants with low activity (R1 
and R2) and variants which had relatively higher activity 
(R71 and R72). Similarly, at 754 DPI, we observed a high 
frequency of R26 (63% activity) coexisting with the pre-
dominant R93 (153% activity). It is possible that 201 and 
754 DPI reflect quasispecies transitions between different 
stages of clinical disease.
Rev quasispecies activity correlates with clinical stage of 
disease
Our analysis of selected Rev variants indicated that 
changes in Rev phenotype were associated with changes 
in clinical disease. As our data show, however, rev vari-
ants existed as a quasispecies population, and no one 
variant can define the phenotype of the quasispecies. To 
determine whether the Rev quasispecies activity was sta-
tistically correlated with different parameters of clinical 
disease, we attempted to approximate the average phe-
notype for the Rev quasispecies at each time point. The 
Figure 5. Variation in Rev-mediated nuclear export activity correlates with temperature and clinical disease. (A) In vitro biological activity of Rev vari-
ants from pony 524. Rev exon 2 variants were inserted into a eukaryotic expression vector and transient transfection assays were performed in 293 
cells as described under Materials and Methods. CAT assays were normalized to the activity of R1 and the results are presented as a percentage of ac-
tivity compared to R1. Error bars denote the standard error of the mean. Variants that differed significantly from the activity of R1 are indicated, with P 
values represented by (*) P < 0.05, (**) P < 0.005, and (***) P < 0.00005). (B) The predicted (open circles, dotted line) and experimental (closed circles, 
solid line) quasispecies Rev activity at different stages of EIAV. The rectal temperature of pony 524 is indicated by solid bars. 
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variants experimentally tested accounted for at least 50% 
of all clones present at each time point. Using the activ-
ity of each tested variant and its frequency in the popula-
tion, we calculated a weighted average to derive an ex-
perimental quasispecies Rev activity at each time point 
(Table 3). Using the phylogenetic relatedness among the 
variants (not shown), the untested Rev variants were each 
assigned the same Rev activity as the nearest tested vari-
ant, and a predicted quasispecies activity was calculated. 
At each time point, the calculated experimental and pre-
dicted quasispecies Rev activities were nearly identical, 
differing at most by 8% (Table 2). Comparison of quasi-
species Rev activity with febrile responses of pony 524 
indicated that the quasispecies Rev activity was highest 
during the recurrent febrile and late febrile stages of EIA 
(Table 3, Figure 5B). These findings further suggested a 
correlation between Rev activity and clinical stage of dis-
ease. Therefore, Pearson correlation coefficients were cal-
culated to test for correlation between the quasispecies 
Rev activity and various clinical parameters, including vi-
rus titer, platelet counts, and temperature of the horse (Ta-
ble 4). No significance was detected in comparisons of 
experimental or predicted quasispecies Rev activity and 
virus titer (P > 0.15) or platelet count (P > 0.45). Analy-
sis by Pearson correlation coefficients found that the tem-
perature of pony 524 was statistically correlated with the 
experimental (P = 0.007) and predicted (P = 0.011) qua-
sispecies Rev activity. In addition, the results of the corre-
lation analyses indicated that phenotypic variation in Rev 
was correlated with changes in clinical stages of EIAV dis-
Table 3. Experimental and Predicted Quasispecies Rev Activity
 Rev variant  R1  R2  R4  R12  R17  R26  R32  R42  R45  R51  R53  R71  R72  R86  R93
 Rev activitya  100  96  222  169  131  63  176  158  193  180  165  162  154  131  153 Tested/ (Exp.) (Pred.)
Stage  DPIb                  totalc  EQRAd  PQRAe
Acute  12  18f  0  0  0  0  1  0  0  0  0  0  0  0  0  0  19/24  98  98
 35 6 2 0 0 2 0 2 0 0 0 0 0 0 0 0 12/23 117 124
Recurrent 67 0 0 0 1 2 0 10 1 1 0 0 0 0 0 0 15/23 169 170
 89 0 0 0 2 1 0 4 3 0 1 1 0 0 0 0 12/24 166 165
 118 0 0 0 2 0 2 0 0 0 0 12 0 0 0 0 16/24 153 158
Afebrile 201 3 4 0 0 1 0 1 0 0 0 0 2 4 0 0 15/25 129 136
 289 9 4 0 0 2 0 1 0 0 0 0 0 0 0 0 16/22 108 117
 385 11 4 0 0 0 0 1 0 0 0 0 0 0 2 0 18/26 107 108
 437 11 4 0 0 1 0 4 0 0 0 0 0 0 0 0 20/23 116 120
Late febrile 754 4 0 0 0 0 6 0 0 0 0 0 0 0 0 10 20/24 115 122
 800 0 0 0 0 0 0 0 0 0 0 0 0 0 1 16 17/23 152 151
a The nuclear export activity level of each variant tested (Ai ), relative to the activity of R1, which is set at 100.
b The days postinfection from which the variants were isolated.
c The number of clones experimentally tested and the total number of clones at each time point.
d The experimental quasispecies Rev activity calculated for each time point.
e The predicted quasispecies Rev activity calculated for each time point.
f  The number of times that variant was detected at that time point (vi ).
Table 4. Correlation between Quasispecies Rev Activity and Clinical Parameters of EIAV Infection
                                                                                            Experimental quasispecies            Predicted quasispecies
                                                                                                       Rev activity                                Rev activity
Clinical parameter  Virus titer  0.157a  0.195a
 Platelet count  0.453a  0.504a
 Temperature  0.007a  0.011a
Clinical disease stage  Acute vs. recurrent  0.013b  0.014b
 Recurrent vs. afebrile  0.010b  0.015b
a P values calculated using Pearson correlation coefficients.
b P values using general linear models.
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ease. The experimental and predicted quasispecies Rev 
activities in the recurrent febrile stage were significantly 
higher than the quasispecies Rev activities in the acute 
period (P = 0.013, P = 0.014) and in the afebrile period (P 
= 0.010, P = 0.015).
Discussion
Antigenic variation in the surface envelope glycopro-
tein has long been recognized as an important mecha-
nism of immune evasion and lentivirus persistence. Re-
cent studies suggested that variation in other regions of 
the viral genome, including the LTR and regulatory genes, 
may also contribute to the clinical disease course (Car-
penter et al., 1991; Maury et al., 1997; Leroux et al., 
1997; Belshan et al., 1998; Hua et al., 1996). We and 
others have observed a high degree of genetic variation in 
the rev exon 2/gp45 region of EIAV (Belshan et al., 1998; 
Leroux et al., 1997), and we previously demonstrated that 
limited amino acid variation in EIAV Rev alters biologi-
cal activity (Belshan et al., 1998). It was proposed that at-
tenuation of the Rev phenotype may allow EIAV to persist 
through down-regulation of viral gene expression and re-
duced replication, enabling the virus to evade an effective 
immune response (Belshan et al., 1998).
To delineate the significance of rev variation in vivo, 
we examined both genetic and biological variation of 
Rev in an experimentally infected pony. Genetic varia-
tion observed in rev during sequential stages of EIAV in-
fection clearly demonstrated that rev variants exist as a 
quasispecies population. Genetic analyses indicated that 
the Rev ORF evolved throughout infection and that ge-
netic variation was the result of selective pressure rather 
than neutral mutations. The frequency at which new 
variants were detected was greatest during clinical peri-
ods, concomitant with higher levels of virus replication 
at these times. Genetic and phenotypic changes in the 
Rev quasispecies coincided with changes in clinical dis-
ease. Rev variants which were predominant during the 
recurrent febrile period had significantly higher nuclear 
export activity than the variants predominant during the 
acute or afebrile periods. Statistical analyses found that 
quasispecies Rev activity was correlated with tempera-
ture of the infected pony but not with virus titer or plate-
let count. Additionally, the quasispecies Rev activity 
in the acute and afebrile stages was significantly lower 
than the quasispecies Rev activity in the recurrent febrile 
stage of disease. Together, these findings indicate that 
variants with high Rev activity have a selective advan-
tage during the recurrent and late febrile stages of EIA in-
fection. Therefore, variation in rev may be a contributing 
factor of EIAV disease progression.
The dynamic evolution of Rev quasispecies during se-
quential stages of clinical EIA is exemplified by changes 
in the frequency of R1. This variant, and the closely re-
lated R2, clearly represented the predominant genotype 
and phenotype in the inoculum and the early time period 
following infection. During the subsequent recurrent fe-
brile period, R1 was replaced by a series of closely re-
lated Rev variants with significantly higher biological 
activity. Surprisingly, R1 reappeared at 201 DPI and pre-
dominated during the prolonged afebrile period. Yet, R1 
was replaced by the more biologically active R93 dur-
ing the late febrile period. These genetic changes in the 
Rev quasispecies were also reflected in the phenotypic 
changes in the quasispecies Rev activity, which was high-
est during the recurrent febrile and late febrile stages of 
disease. In total, these findings indicate that there were 
changes in selective pressure at sequential stages of clin-
ical disease. Specifically, our results suggest that changes 
in the host environment occurred during the recurrent fe-
brile period and, further, that these changes selected for 
variants with significantly higher Rev activity. At present, 
the selective pressures present during the recurrent febrile 
period are not yet known. Increased Rev activity did not 
correlate with virus titer, as might be expected if the se-
lective advantage was solely dependent on the virus repli-
cation rate. It is possible that a Rev-specific host immune 
response selects for different Rev variants; however, im-
mune evasion does not explain the significant differences 
in the biological activity of selected Rev variants. Ongo-
ing studies to identify factors important in selection of Rev 
variants may increase our understanding of mechanisms 
of EIAV pathogenesis.
Viremia has long been associated with clinical epi-
sodes in EIAV-infected animals (Issel and Coggins, 1979). 
The abrogation of recurrent clinical episodes is typically 
coincident with the maturation of the host immune re-
sponse and decline in virus replication (Hammond et al., 
1997). The appearance of broadly acting neutralizing an-
tibody in pony 524 at 201–289 DPI was associated with 
the resolution of the recurrent febrile period, although vi-
rus load remained high through most of the afebrile pe-
riod. Our model predicted that Rev variant that predom-
inated during febrile periods would differ phenotypically 
from variants predominant during afebrile periods. Indeed, 
the quasispecies Rev activity was significantly higher in 
the recurrent febrile period than in the afebrile period. 
However, our model did not predict that quasispecies ac-
tivity in the acute period would differ significantly from 
that in the recurrent febrile period, nor that the acute and 
afebrile periods would be so genetically and phenotypi-
cally similar. The predominance of R1 during the acute 
period indicates that R1 is a robust phenotype, capa-
ble of supporting high levels of virus replication. In fact, 
the predominance of R1 throughout the afebrile period 
was associated with relatively high levels of viremia and 
thrombocytopenia that persisted until late in the afebrile 
stage of disease (754 DPI). If pony 524 had resolved to a 
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clinically inapparent state, in which virus load decreased 
to nearly undetectable levels and platelet counts returned 
to normal levels, it is possible that the quasispecies Rev 
activity would have been statistically correlated with vi-
rus load, or that Rev variants less active than R1 would 
have been predominant during the afebrile period. In sup-
port of this, the least-active variant, R26, comprised 25% 
of the observed population at 754 DPI, where virus loads 
were barely above the threshold of detection and platelet 
counts were near normal levels.
The second exon of Rev is completely overlapped by 
a portion of the cytoplasmic tail of the EIAV transmem-
brane protein gp45. Thus, nucleotide substitutions in this 
region may alter Rev and/or gp45. Because of the con-
straints of maintaining functional proteins in both reading 
frames, it might be expected that variation in this region 
would be biologically significant. However, it is not im-
mediately obvious which reading frame determines selec-
tive advantage. Previous studies of variation in rev/ gp41 
of HIV-1 suggested that both genes evolved independently 
and that the changes were the result of selection in only 
one ORF (Martins et al., 1991). Our data would argue that 
EIAV rev/gp45 evolved as a result of selective pressures 
in both reading frames. The overall complexity (number 
of aa variants at each time point) of Rev and gp45 was 
approximately the same throughout infection, and out of 
146 nt variants, there was a similar number of total Rev 
and gp45 aa variants (101 and 105, respectively). This 
suggests that changes in gp45 also contribute to the selec-
tive advantage of the observed rev/gp45 variants. The cy-
toplasmic tail of TM plays important and varied roles in 
lentivirus replication, and studies are ongoing to charac-
terize the effect of gp45 variation on EIAV replication. It 
is probable that variation in both ORFs contribute to virus 
pathogenicity in vivo.
The underlying assumptions of the RT-PCR method are 
that all viral quasispecies are amplified with equal effi-
ciency and that the resulting proportions are representa-
tive of the starting population. Although these assumptions 
have generally been accepted, some reports suggest that 
PCR amplification might result in selective amplification 
of individual templates, especially in reactions containing 
a heterogeneous population of templates (Polz and Cava-
naugh, 1998; Suzuki and Giovannoni, 1999; Barnard et 
al., 1998; Suzuki et al., 1998). Previous studies suggested 
that interactions between primers and templates might al-
ter the efficiency of template amplification and, thus, al-
ter the sample population (Barnard et al., 1998; He et al., 
1994; Suzuki and Giovannoni, 1999), or that primer pairs 
may systematically bias PCR amplification (Suzuki and 
Giovannoni, 1999; Polz and Cavanaugh, 1998; Barnard 
et al., 1998). However, these studies have generally in-
volved two or three different templates of known concen-
trations. The complex nature of viral quasispecies in vivo 
can further complicate sequencing studies. Our statistical 
analyses of primer-pair bias in the inoculum indicated that 
the frequency of observed variants was not systematically 
biased during PCR amplification, so the random samples 
were likely reflective of variant frequencies in vivo. The 
risk of bias may have been reduced by designing prim-
ers to conserved target sequences and using primers with 
similar GC content and optimal annealing temperatures. 
Taken together, our results suggest that randomly sampled 
viral populations obtained by RT-PCR can reflect in vivo 
populations. This offers confidence in the characteriza-
tion of viral quasispecies present in vivo and strengthens 
interpretations of studies examining the role of virus varia-
tion in immune evasion and disease progression.
Most studies of EIAV persistence in vivo used a cloned, 
cell-culture-propagated virus as an inoculum and were 
limited to analysis of febrile periods. Inocula comprised 
of a homogenous population of virus have been useful in 
identifying genetic changes that arise during an in vivo in-
fection. In this study, our intention was to better reflect a 
naturally occurring infection in an experimentally infected 
animal. Therefore, the inoculum used was obtained from 
a donor pony undergoing its first fever episode and repre-
sented a heterogeneous population of virus rather than a 
single clonal population. Although this method required 
a more extensive analysis, we believe it provided an ac-
curate representation of the complex nature of EIAV evo-
lution throughout disease within a single infected pony. 
The heterogeneous nature of the inoculum, in combina-
tion with the extensive sampling and genetic analysis at 
sequential time points, allowed us to examine the genetic 
variants that made up the rev quasispecies and the bio-
logical phenotype of the Rev quasispecies that were se-
lected at variable stages of clinical disease. It is clear that 
genetic and phenotypic changes in the Rev quasispecies 
were associated with changes in clinical stages of disease 
in this pony. While analysis of additional EIAV-infected 
ponies is needed to fully elucidate the biological signifi-
cance of Rev variation, the findings presented here indi-
cate that variation in virus regulatory proteins can contrib-
ute to lentivirus persistence.
Materials and Methods
Experimental infection
The experimental infection of pony 524 was previously 
reported (Oaks et al., 1998). The pony was infected in-
travenously with 103 horse infectious doses of the highly 
virulent Wyoming strain of EIAV (EIAVWyo). Physical ex-
aminations, rectal temperatures, hemograms, and platelet 
counts were performed daily during clinical episodes and 
intermittently during chronic clinical disease or subclini-
cal infection. Sera and plasma were collected, processed, 
and stored at –80°C until analyzed.
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Virus neutralization assay
Assays were performed using equine dermal (ED) 
cells maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 20% fetal bovine serum, pen-
icillin, and streptomycin as previously described (Carpen-
ter et al., 1987). ED cells were seeded 1 day prior to infec-
tion at 105 cells/well in a six-well dish. Serum from pony 
524 was heat-inactivated at 60°C, to destroy complement, 
and was serially diluted twofold in supplemented media. 
Five hundred focus-forming units of EIAVWSU-5, a cell cul-
ture-derived strain of EIAVWyo (O’Rourke et al., 1988), in 
a 100-μl volume was incubated with 100 μl of serially di-
luted pony 524 serum at 37°C for 1 h. Duplicate wells of 
ED cells were inoculated with 100 μl of virus–serum mix-
ture in the presence of 8 μg/ml polybrene, and the media 
was changed the following day. Cells were incubated for 
an additional 72 h and fixed with 100% methanol, and 
immunocytochemistry was performed using convalescent 
anti-EIAV horse sera to detect foci of virus-infected cells 
(Carpenter et al., 1987). Results are expressed as the se-
rum neutralization titer, defined as the reciprocal of the 
highest serum dilution that gave an 80% reduction in foci 
as compared with that of preimmune and negative con-
trol serum.
Amplification and sequence analysis of viral variants 
EIAVWyo inoculum was obtained as a serum sample 
collected from an experimentally infected foal experienc-
ing its initial fever episode at 7 days postinfection (DPI). 
To obtain viral RNA, 100 μl of EIAVWyo inoculum or pony 
524 serum was pelleted by centrifugation at 93,000g for 
1 h at 4°C. Viral RNA was isolated from these pellets by 
guanidine thiocyanate lysis and acid phenol–chloroform 
extraction using a commercially available kit (Ambion, 
Austin, TX) and resuspended in 24 μl RNase-free glass-dis-
tilled water containing 0.1 mM EDTA. RNA samples were 
DNase I treated using the methods of Huang et al. (1996). 
Briefly, two units of DNase I (Ambion) were added to 3 μl 
of viral RNA, 20 mM MgCl2, 1 mM of each dNTP, 1× PCR 
buffer II (Perkin–Elmer, Branchburg, NJ), 20 units of RNase 
inhibitor, and 2.5 μM of random hexamers in a total vol-
ume of 20 μl. The reaction was incubated at 37°C for 30 
min and heated to 75°C for 5 min to inactivate the DN-
ase I. After cooling to 4°C, 50 units of Moloney murine 
leukemia virus reverse transcriptase were added. Reac-
tions were incubated at 42°C for 45 min, heated to 99°C 
for 5 min to inactivate the reverse transcriptase, and then 
cooled to 5°C for 5 min. The reaction was brought up to 
100 μl in 1× PCR buffer II with 2 mM MgCl2, 0.2 μM of 
each dNTP, 2.5 units Taq polymerase (Perkin–Elmer), and 
1 μM of each primer.
Primers were designed based on conserved regions 
flanking the second exon of rev (Table 1). PCR amplifica-
tion conditions consisted of 37 cycles of denaturation at 
94°C for 2 min, annealing at 50°C for 1 min, and exten-
sion at 72°C for 1 min. The initial and final cycles con-
tained a prolonged extension at 72°C for 5 min. A 2-μl 
aliquot of PCR product was TA-cloned into pGEM-T vec-
tors as recommended by the manufacturer (Promega, 
Madison, WI) and transformed into Escherichia coli DH-
5. Positive clones were identified by colony blot hybrid-
ization using a subgenomic fragment of rev labeled with 
[32P]dTTP by random-primed labeling (Roche Molecu-
lar Biochemicals, Indianapolis, IN). Plasmids were iso-
lated from positive clones using a commercially available 
kit, Wizard Plus Miniprep (Promega), and the rev inserts 
were sequenced bidirectionally with vector primers flank-
ing the insert. All sequencing was performed by the Iowa 
State University DNA Synthesis and Sequencing Facil-
ity using an automated DNA sequencer. Sequences were 
aligned by MacVector and AssemblyLIGN software (Ox-
ford Molecular, Beaverton, OR). To estimate the RT-PCR 
error rate, viral mRNA was isolated from a clonal cell line 
stably transfected with an EIAV proviral DNA clone, re-
verse transcribed and amplified with Taq polymerase. The 
amplicons were cloned and 17 individual clones were se-
quenced. The error rate of the RT-PCR amplification pro-
cedure was determined to be 0.025%, or three substitu-
tions per 11,991 base pairs sequenced. 
Construction of Rev expression vectors
rev variants were subcloned into pERevWT, a Rev ex-
pression vector previously described as pcH21 (Belshan 
et al., 1998). This plasmid contains Rev cDNA in the 
pCR3 background (Invitrogen, Carlsbad, CA). pERevWT 
was digested with the restriction endonuclease ApaI to re-
move rev exon 2. The digested plasmid was gel-purified, 
dephosphorylated, and ligated with the exon 2 sequence 
variants. Two methods, based on the direction of the in-
serts in pGEM-T, were employed to move variant exon 2 
sequences into the pERevWT background. Inserts in the 
“forward” direction were digested with ApaI, gel-puri-
fied, and ligated into the digested pcRevWT background. 
Inserts in the “reverse” orientation were PCR-amplified 
with the EM7160 primer and a 3′ EIAV primer contain-
ing an ApaI site (underlined): 5′-CTGGGCCCTCATAAAT-
GTTTCCTCCTTCGC. The PCR products were purified, 
digested with ApaI, and ligated into the pcRevWT back-
ground. All clones were verified for directionality by re-
striction mapping and confirmed by sequencing.
Statistical analyses
A two-dimensional chi-square test was used to test 
the null hypothesis that the frequency distribution of ob-
served variants and the choice of primer pairs was in-
dependent. The chi-square statistic was calculated, and 
the P value was determined for each contingency table. 
The statistical threshold used in this study was 95% con-
fidence. Subset pairwise analyses were also performed 
on the data, and the results were interpreted with Bon-
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ferroni’s correction (Miller, 1981). For the Monte Carlo 
simulation (Rubinstein, 1981) comparing the four primer 
pairs, the chi-square distance was calculated between 
the four sets of simulated data. The data were simulated 
10,000 times, and experimentally observed chi-square 
distances were compared with the 10,000 simulated dis-
tances to find the percentile ranking, which correlates to 
the P value. For the pairwise analyses of primer pairs, 
10 variants were randomly created for each set of the 
two simulated primer pairs. The remainder of the sim-
ulation was the same as just described, except the Kull-
back distance (Bishop et al., 1975) was calculated rather 
than chi-square distance.
The transition to transversion ratio and the nonsynon-
ymous-to-synonymous mutation ratio were calculated us-
ing the program SITES, version 1.1 (Hey and Wakeley, 
1997). The Tajima test (Tajima, 1989), which determines 
whether nucleotide variation within a region was the re-
sult of selective pressure or neutral mutations, was also 
performed using SITES.
The experimental quasispecies Rev activity (QRA) for 
each time point was calculated as the average Rev activ-
ity of tested variants, weighted by frequency of the tested 
variants, using the following equation:
[insert equation]
where n is the number of different variants tested, vi is 
the number of times variant i was detected at that time 
point, and Ai is the Rev activity level for variant i. A phy-
logenetic tree was constructed, and untested variants 
were assigned the same activity as the nearest tested 
variant in the tree. These values were used to estimate 
the predicted quasispecies Rev activity in a manner sim-
ilar to the calculation of the experimentally Rev quasi-
species activity. The statistical package SAS, version 6.03 
(SAS Institute, 1988), was used to examine possible cor-
relation between the experimental and predicted quasi-
species Rev activity and different parameters of clinical 
disease. Pearson correlation was used to test virus titer, 
platelet counts, and temperature of the infected pony. 
A quadratic model was used to fit the relationship be-
tween quasispecies Rev activity and temperature, and 
analysis of the studentized residuals was used to test the 
quadratic model. Comparison of quasispecies Rev activ-
ity between different stages of disease was done using a 
general linear models procedure, adjusted for multiple 
comparisons by Tukey–Kramer correction. 
Quantification of virus load
RNA quantification standards were synthesized by in 
vitro transcription from a linearized plasmid containing a 
450-base pair fragment of EIAV gag (pEIAp26.1). The RNA 
was purified by extraction with Trizol reagent, treated 
with 6 U of DNase I (Ambion) for 45 min at 37°C to re-
move plasmid DNA, and then extracted again with Trizol 
reagent. Final RNA preparation was quantified by spectro-
photometry, aliquoted, and stored at –80°C. The absence 
of contaminating plasmid DNA was verified by PCR with-
out reverse transcription.
To create standards, known copy numbers of RNA 
standards were assayed in triplicate as described below; 
these included 2 × 107, 2 × 106, 2 × 105, 2 × 104, and 
2 × 103 copies of RNA. Reaction products were visual-
ized in ethidium bromide-stained agarose gels, and their 
densities quantified using a commercial digital imaging 
system (IS1000; Alpha Innotech, San Leandro, CA). The 
mean density for each copy number was plotted against 
the log10 of the copy numbers to construct a standard 
curve.
The one-tube, semiquantitative RT-PCR protocol was 
modified from that described by Hamel et al. (1995). The 
reaction buffer contained 50 mM KCl, 10 mM Tris (pH 
9.0), 0.1% Triton X-100, and 2.0 mM MgCl2, and each 
reaction contained 0.4 mM deoxyribonucleotide mix 
(Roche Molecular Biochemicals), 1 U of RNase inhibi-
tor (Roche Molecular Biochemicals), 20 U of Moloney 
murine leukemia virus reverse transcriptase (SuperScript 
II; Gibco BRL, Rockville, MD), 1.5 U of Taq DNA poly-
merase (Gibco BRL), and 90 pmol of the forward primer 
(5′- ACTACTTGGGTGAATACCAT) and 90 pmol of the re-
verse primer (5′-TCTGCCTAAACTGATCAAAA) in a final 
volume of 25 μl. These oligonucleotides prime both re-
verse transcription as well as the subsequent PCR reac-
tion, and amplify a 322-base pair segment of the EIAV 
capsid protein gene (p26) (nts 897–1199). Amplification 
was performed as follows: 42°C for 40 min, DNase I in-
activation at 95°C for 3 min, and 40 cycles of 94°C for 30 
s, 58°C for 30 s, and 72°C for 30 s. Each RT-PCR run in-
cluded positive and negative controls. Complete removal 
of all DNA from samples was confirmed by performing a 
duplicate reaction without reverse transcriptase. Follow-
ing amplification, 13 μl of the PCR reaction was analyzed 
by electrophoresis through 2.0% agarose and visualized 
by ethidium bromide staining and ultraviolet light. Serum 
samples from each time point were assayed in duplicate, 
and their mean density values were used to calculate copy 
numbers of viral RNA from the standard curve. RT-PCR re-
actions for standards and samples were performed simul-
taneously using a reagent–master mix, and were analyzed 
simultaneously in a single agarose gel.
CAT assays
293 cells were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf se-
rum and penicillin/streptomycin. Transient transfections 
and CAT assays were performed using 293 cells as previ-
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ously described (Belshan et al., 1998). Briefly, 1 μg of ei-
ther pcDNA3 or Rev variant plasmid was transfected by 
calcium phosphate coprecipitation with 0.2 μg of pERRE-
All reporter plasmid, 0.2 μg of pCH110 (Amersham Phar-
macia Biotech, Piscataway, NJ), and 0.6 μg of pUC19. 
pERRE-All, a derivative of pDM138 containing EIAV nts 
5280–7534, was described previously (Belshan et al., 
1998). Each experiment also included a sham group, 
which contained no reporter plasmid, but an additional 
0.2 μg of pUC19. Two days posttransfection, cells were 
harvested, resuspended in 0.3 ml 0.25 M Tris (pH 7.5), 
lysed by freeze/thawing, and assayed for β-galactosidase 
activity, to normalize CAT assays for transfection effi-
ciency. Normalized lysates were assayed for CAT activity 
in a 0.1 ml volume with 3 μl [14C]chloramphenicol and 1 
mM acetyl CoA. Acetylated products were separated by 
thin-layer chromatography and the percentage of acety-
lation was determined by quantification by phosphorim-
ager. Experiments were performed in triplicate and results 
summarize a minimum of nine independent transfec-
tions. Statistical significance was determined by analysis 
of variance.
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